Compare Stocks: AQXP, NKTR, VCEL, and NUVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQXP Aquinox Pharmaceuticals	$21.61 +3.3%	$3.94	$2.00 ▼ $3.84	$508.70M	-7.37	239,362 shs	89,409 shs
NKTR Nektar Therapeutics	$57.06 -3.9%	$70.99	$33.40 ▼ $109.00	$1.95B	1.14	1.23 million shs	2.56 million shs
NUVB Nuvation Bio	$5.75 +0.3%	$6.45	$2.99 ▼ $9.75	$2.02B	1.52	4.50 million shs	2.82 million shs
VCEL Vericel	$39.71 +1.0%	$42.56	$28.95 ▼ $49.32	$2.03B	1.04	472,516 shs	359,339 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQXP Aquinox Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+28.25%
NKTR Nektar Therapeutics	0.00%	-14.96%	-23.46%	-10.35%	-5.42%
NUVB Nuvation Bio	0.00%	-1.54%	-17.87%	+2.50%	+78.14%
VCEL Vericel	0.00%	-0.77%	-3.57%	-14.10%	+31.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQXP Aquinox Pharmaceuticals	$21.61 +3.3%	$3.94	$2.00 ▼ $3.84	$508.70M	-7.37	239,362 shs	89,409 shs
NKTR Nektar Therapeutics	$57.06 -3.9%	$70.99	$33.40 ▼ $109.00	$1.95B	1.14	1.23 million shs	2.56 million shs
NUVB Nuvation Bio	$5.75 +0.3%	$6.45	$2.99 ▼ $9.75	$2.02B	1.52	4.50 million shs	2.82 million shs
VCEL Vericel	$39.71 +1.0%	$42.56	$28.95 ▼ $49.32	$2.03B	1.04	472,516 shs	359,339 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQXP Aquinox Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+28.25%
NKTR Nektar Therapeutics	0.00%	-14.96%	-23.46%	-10.35%	-5.42%
NUVB Nuvation Bio	0.00%	-1.54%	-17.87%	+2.50%	+78.14%
VCEL Vericel	0.00%	-0.77%	-3.57%	-14.10%	+31.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQXP Aquinox Pharmaceuticals	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.77	Moderate Buy	$138.50	142.73% Upside
NUVB Nuvation Bio	2.69	Moderate Buy	$13.00	126.28% Upside
VCEL Vericel	2.67	Moderate Buy	$58.40	47.07% Upside

Current Analyst Ratings Breakdown

Latest AQXP, NKTR, VCEL, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/16/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/16/2026	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$10.00
9/16/2026	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
8/28/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	NKTR Nektar Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	NUVB Nuvation Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQXP Aquinox Pharmaceuticals	$25M	20.35	N/A	N/A	$3.09 per share	6.99
NKTR Nektar Therapeutics	$55.23M	35.27	N/A	N/A	$4.41 per share	12.94
NUVB Nuvation Bio	$62.90M	32.07	N/A	N/A	$0.88 per share	6.53
VCEL Vericel	$276.26M	7.36	$0.56 per share	71.49	$7.01 per share	5.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQXP Aquinox Pharmaceuticals	-$31.58M	N/A	N/A	N/A	N/A	N/A	-30.13%	-28.08%	N/A
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	84.49	47.27	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)

Latest AQXP, NKTR, VCEL, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQXP Aquinox Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQXP Aquinox Pharmaceuticals	N/A	63.17	63.17
NKTR Nektar Therapeutics	N/A	10.42	10.42
NUVB Nuvation Bio	0.96	8.37	8.14
VCEL Vericel	N/A	5.04	4.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQXP Aquinox Pharmaceuticals	71.69%
NKTR Nektar Therapeutics	75.88%
NUVB Nuvation Bio	61.67%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
AQXP Aquinox Pharmaceuticals	4.00%
NKTR Nektar Therapeutics	2.50%
NUVB Nuvation Bio	30.11%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQXP Aquinox Pharmaceuticals	8	23.54 million	N/A	Not Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
NUVB Nuvation Bio	305	351.12 million	245.40 million	Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable

AQXP, NKTR, VCEL, and NUVB Headlines

Recent News About These Companies

Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain

September 26 at 11:11 PM | finance.yahoo.com

Vericel Corporation (NASDAQ:VCEL) Stock Has Average Price Target of $58.40

September 25 at 6:13 AM | marketbeat.com

Bank of America Corp DE Invests $45.21 Million in Vericel Corporation $VCEL

September 22, 2026 | marketbeat.com

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

September 14, 2026 | seekingalpha.com

Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP

September 12, 2026 | marketbeat.com

Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

September 10, 2026 | marketbeat.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

September 8, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Vericel Corporation $VCEL

September 5, 2026 | marketbeat.com

115,630 Shares in Vericel Corporation $VCEL Bought by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Man Group plc Buys New Shares in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Formula Growth Ltd. Makes New $1.15 Million Investment in Vericel Corporation $VCEL

August 28, 2026 | marketbeat.com

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares

August 1, 2026 | insidertrades.com

Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

July 30, 2026 | zacks.com

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

July 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQXP, NKTR, VCEL, and NUVB Company Descriptions

Aquinox Pharmaceuticals NASDAQ:AQXP

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Nektar Therapeutics NASDAQ:NKTR

$57.06 -2.32 (-3.91%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$57.53 +0.47 (+0.82%)

As of 09/25/2026 07:30 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nuvation Bio NYSE:NUVB

$5.74 +0.02 (+0.26%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$5.82 +0.08 (+1.36%)

As of 09/25/2026 07:57 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Vericel NASDAQ:VCEL

$39.71 +0.41 (+1.04%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$39.81 +0.10 (+0.25%)

As of 09/25/2026 07:58 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQXP, NKTR, VCEL, and NUVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQXP, NKTR, VCEL, and NUVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQXP, NKTR, VCEL, and NUVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQXP, NKTR, VCEL, and NUVB Company Descriptions

Aquinox Pharmaceuticals NASDAQ:AQXP

Nektar Therapeutics NASDAQ:NKTR

Nuvation Bio NYSE:NUVB

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQXP, NKTR, VCEL, and NUVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQXP, NKTR, VCEL, and NUVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQXP, NKTR, VCEL, and NUVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQXP, NKTR, VCEL, and NUVB Company Descriptions

Aquinox Pharmaceuticals NASDAQ:AQXP

Nektar Therapeutics NASDAQ:NKTR

Nuvation Bio NYSE:NUVB

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools